ReviewCellular and molecular life sciences : CMLS2015
Chromogranin A: a paradoxical player in angiogenesis and vascular biology.
Review in Cellular and molecular life sciences : CMLS, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Effects of Supplementation with Microalgae Extract fromNutrients · 2025Trial
- Endometriosis Is Associated with Increased Serum and Peritoneal Fluid Concentrations of Chromogranin A and Its Derivatives.Journal of clinical medicine · 2026Article
- A complex role of chromogranin A and its peptides in inflammation, autoimmunity, and infections.Frontiers in immunology · 2025Review
- Inhibitory effect of anti-Scg3 on corneal neovascularization: a preliminary study.BMC ophthalmology · 2022Article
- Neuropilin-1 and Integrins as Receptors for Chromogranin A-Derived Peptides.Pharmaceutics · 2022Review
- Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization.The FEBS journal · 2022Article
- Lack of evidence of mastitis as a causal factor for postpartum dysgalactia syndrome in sows.Translational animal science · 2020Article
- Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma.Frontiers in oncology · 2020Article
- Catestatin reverses the hypertrophic effects of norepinephrine in H9c2 cardiac myoblasts by modulating the adrenergic signaling.Molecular and cellular biochemistry · 2020Article
- Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation.Annals of the New York Academy of Sciences · 2019Review
- Secretogranin III as a novel target for the therapy of choroidal neovascularization.Experimental eye research · 2019Article
- Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression.Frontiers in oncology · 2019Review
- Hormonal and metabolic indicators before and after farrowing in sows affected with postpartum dysgalactia syndrome.BMC veterinary research · 2018Article
- Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine.Endocrine connections · 2018Article
- Ligandomics: a paradigm shift in biological drug discovery.Drug discovery today · 2018Review
- Secretogranin III: a diabetic retinopathy-selective angiogenic factor.Cellular and molecular life sciences : CMLS · 2018Review
- Secretogranin III promotes angiogenesis through MEK/ERK signaling pathway.Biochemical and biophysical research communications · 2018Article
- Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.Pflugers Archiv : European journal of physiology · 2018Review
- Chromogranins: from discovery to current times.Pflugers Archiv : European journal of physiology · 2018Review
- Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy.The Journal of experimental medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Half a century after the discovery of chromogranin A as a secreted product of the catecholamine storage granules in the bovine adrenal medulla, the physiological role for the circulating pool of this protein has been recently coined, namely as an important player in vascular homeostasis. While the circulating chromogranin A since 1984 has proved to be a significant and useful marker of a wide range of pathophysiological and pathological conditions involving the diffuse neuroendocrine system, this protein has now been assigned a physiological "raison d'etre" as a regulator in vascular homeostasis. Moreover, chromogranin A processing in response to tissue damage and blood coagulation provides the first indication of a difference in time frame of the regulation of angiogenesis evoked by the intact chromogranin A and its two major peptide products, vasostatin-1 and catestatin. The impact of these discoveries on vascular homeostasis, angiogenesis, cancer, tissue repair and cardio-regulation will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.